Company ProfilePremium

AusCann Group Holdings Ltd

Company Profile Analysis

Ticker: AC8.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
AusCann Group Holdings Ltd - Company showcase

Year Founded & Workforce

2014

AusCann Group Holdings Ltd logo

AusCann Group Holdings Ltd Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

AusCann Group Holdings Ltd Overview

AusCann Group Holdings is a Perth-based, formerly ASX-listed cannabinoid pharmaceutical developer that never achieved commercial scale. It was formed in 2014 as one of Australia's first licensed medicinal-cannabis ventures and listed in 2017 via a reverse takeover with backing from Canopy Growth. It then pivoted from cultivation (Chile's DayaCann JV, a Tasmanian Alkaloids partnership) toward standardised, pharmaceutical-grade dose forms, culminating in the Neuvis® SEDDS hard-shell capsule launched in February 2020. The 2021 scrip acquisition of veterinary developer CannPal added an animal-health pipeline that was fully impaired within 15 months. Since 2022 AusCann has been in managed wind-down and monetisation mode. It sold its Wangara facility, lent heavily to European Cannabis Corporation (EuroCann/ECC, with A$9.6m later impaired), and was removed from the ASX in 2024. In April 2026 it sold its 48% CannPal stake to Argent BioPharma for 20m RGT shares and granted Argent an option over the Neuvis IP. Today it is effectively an unlisted holding vehicle for residual IP, an ECC equity interest and Argent shares.


Company's own description (FY2023 Annual Financial Statements): AusCann describes its principal activity as developing a differentiated portfolio of innovative, standardised cannabinoid-based medicines that expand the therapeutic applications of cannabis for both people and pets. It positions itself as supplying healthcare professionals and veterinarians with reliable pharmaceutical and nutraceutical products backed by safety, quality and efficacy data, in jurisdictions with relevant legislation.

Independent characterisation. In substance, AusCann has evolved through four business models:

  1. Cultivator / supply-chain aggregator (2014–2018). Licences, cultivation plans (Norfolk Island, then Tasmania with Tasmanian Alkaloids, plus the DayaCann JV in Chile) and a distribution arrangement with Australian Pharmaceutical Industries.

  2. Specialty pharma formulator (2018–2022). The proprietary self-emulsifying drug delivery system (SEDDS) powder formulation became Neuvis® hard-shell capsules, sold under the TGA Special Access Scheme Category B (SAS-B). The business was a B2B2C product model: prescribers recommend, pharmacies dispense. Sales never exceeded roughly A$84k in any year, and COGS exceeded sales in FY2022. Management itself stated that Neuvis was uneconomic at the existing production cost.

  3. Human plus animal health pipeline (2021–2023). Through CannPal: CPAT-01 (THC/CBD canine osteoarthritis pain, Phase II), DermaCann® (CBD nutraceutical for canine atopic dermatitis) and MicroMAX® (CSIRO-licensed microencapsulation).

  4. Asset-holding / transactional vehicle (2022–present). Its revenue comprised R&D tax incentive refunds, rental income from the Wangara facility (until June 2023) and accrued interest on ECC loans. It also held an exclusive AU/NZ agency for ECC's German EU-GMP HAPA pharm flower and extracts (expanded July 2023). The commercial outcome of that agency is not publicly disclosed.

Revenue model mix (FY2023, audited): product sales nil; government grants 1,249 (57.6% of total income); interest 619 (28.5%); rent 302 (13.9%). Total income was 2,170 A$000. Licensing income is nil to date. Prospective licensing or royalty streams exist only via the Argent Neuvis option, which carries a production royalty in AusCann's favour if exercised.

Value-chain position: formerly an upstream licence holder, then a mid-stream formulator using contract manufacturers (Ausphex Pty Ltd process development for Neuvis, Nov 2021, A$195k commitment). It has no owned manufacturing today.

Customer types / end-markets: Australian prescribers and pharmacies (human medicinal cannabis, SAS-B and Authorised Prescriber pathways). Veterinarians and pet owners were targeted via CannPal (US FDA-CVM INAD file established for CPAT-01). European pharmaceutical markets were addressed indirectly via ECC and the SEDDS licence granted to ECC for Europe.

Strategy

Stated strategy themes (FY2023 AFS):

  • Develop a differentiated portfolio of standardised cannabinoid medicines for people and pets.

  • Provide prescribers and veterinarians with products backed by robust safety, quality and efficacy data.

  • Operate in jurisdictions offering a compelling return on investment.

  • Actively review the R&D portfolio "with a view to undertake a transaction or a series of transactions which may involve strategic acquisitions and disposals."

Initiatives in the last ~24–36 months:

Medium-term financial targets / guidance: none publicly disclosed. ESG and sustainability commitments: none disclosed. Cost programmes: FY2023 disclosures emphasised operating-cost reductions (1H FY2023 cash costs down 39%), but no formal targets were given.

Products & Services

Human health (Medicinal Cannabis R&D segment)

Product / platformDescription & capabilitiesTarget customerLaunch / statusPricing
Neuvis® hard-shell capsulesProprietary SEDDS technology combining silica, cannabis extract, MCT oil and excipients into a free-flowing powder that can deliver single cannabinoids or ratios. The powder is encapsulated in hard-shell capsules in blister packs. Previously launched ratios: 2.5:2.5 mg and 10:10 mg THC:CBD for chronic pain (per vendor summary). A Phase 1 PK/safety study in 25 subjects met all endpoints (FY2021). The FY2023 process-improvement plan delivered longer shelf life (reduced THC degradation) and shorter manufacturing time. Argent claims 3–5× bioavailability and patents to 2038+ (counterparty claim).Australian prescribers and pharmacies via SAS-B / Authorised PrescriberLaunched Feb 2020. Commercially uneconomic per management (FY2023). Argent holds an option over the IP, exercisable within 12 months of 13 Apr 2026 for A$2m in RGT shares plus a production royalty to AusCann.—
SEDDS technology licence (Europe)Exclusive licence to ECC of SEDDS "in its current form" for Europe, to develop a standardised dose form for GermanyECCGranted FY2023—
CannEpil® CMC / dossier in-licenceAusCann licensed Argent's CannEpil chemistry, manufacturing and controls data and dossier for non-epilepsy programmesInternal pipelineHoA Apr 2025; deferred fee plus royaltiesDeferred licence fee structure

Distribution (third-party products)

ProductDescriptionTargetStatus
HAPA pharm THC/CBD cannabis flowers (Cannabis Flos)German EU-GMP raw flower manufactured by ECCAU/NZ prescribers and pharmaciesExclusive AU/NZ agency from 31 Jul 2023; A$2.25m paid as a stock deposit in FY2023 (A$2.2m stock secured)
HAPA pharm full-spectrum CBD extracts (<0.2% THC)CBD concentrations from under 2% to over 25%AU/NZAs above
HAPA pharm THC/CBD full-spectrum extractsMultiple concentrations; individualised productionAU/NZAs above; ECC supplies TGO 93 compliance documentation

Sales volumes under the agency are not publicly disclosed.

Animal health (CannPal — held 2021–2026, now Argent's)

AssetDescriptionStatus at exit
CPAT-01Liquid oral veterinary medicine with standardised THC and CBD whole-plant extracts in a proprietary ratio, targeting canine pain and inflammation. Studied in over 100 dogs, including a randomised double-blind placebo-controlled trial in 46 client-owned dogs with osteoarthritis. FDA-CVM INAD file established.Phase II at the FY2023 AFS. Argent's June 2026 quarterly reports Phase 2C dose confirmation completed and advancement toward Phase 3.
DermaCann®CBD-derived nutraceutical (oral oil, patented combination with bioactive lipids) for canine skin and immune health / atopic dermatitis. A 90-day US Target Animal Safety study was completed (1H FY2022).Development
MicroMAX®CSIRO patented microencapsulation; global exclusive rights in animal therapeutics (granted FY2020)Platform

Accounting note: CannPal IP of A$17.49m was recognised on acquisition and fully impaired at 30 June 2022 (A$15.46m impairment after A$2.03m amortisation). Patents expire 2039–2040 and trademarks renew 2029–2030 (FY2023 AFS Note 11).

Discontinued / legacy

AssetDescriptionStatus
DayaCann (Chile)50% JV cultivating medicinal cannabis in Chile for trial formulationsSold March 2021; arbitration under Chilean law over US$1.0m deferred consideration
Wangara R&D facility (11 Excellence Drive)Cultivation, extraction and NPD site in WA; leased to Source Certain InternationalSold 9 Jun 2023 for A$6.74m
Tasmanian Alkaloids cultivation partnershipWestbury, TasmaniaNot pursued; status not publicly disclosed

Financial Narrative

Sources: FY2023 Annual Financial Statements (audited; includes the five-year loss/EPS table in the Remuneration Report); 1H FY2023 and 1H FY2022 Appendix 4D; FY2021 results commentary (30 Aug 2021). Sales for FY2019–FY2021 come from Barchart (third-party, flagged). FY2024 onward: no annual accounts were located.

Income statement

Notes: FY2021 impairment reflects the A$2.593m inventory write-down. FY2022 impairments total A$20.26m (derived): intangibles 15,459, investment property 3,855, fixed assets 759 and inventory 183. FY2023 impairments total A$9.94m (derived): ECC loans and interest 9,615 and investment-property loss 323. EBITDA and operating income are not reported. On any definition they are deeply negative: FY2023 continuing loss before tax was -10,701, of which D&A was only 182.

Data conflict flag: Barchart shows FY2023 net income of -1,045 (A$000) versus the audited -10,919. The audited figure is used. Wikipedia's infobox lists "Revenue A$1,981,664,000 (2023)" and "Total assets A$18,450,158,000". These are scaling errors: the true figures are A$1.98m total income and A$18.45m total assets, and both relate to FY2022, not FY2023.

Margins and growth

Revenue CAGR is not meaningful (product sales were nil in both FY2019 and FY2023).

Balance sheet

FY2019 and FY2020 cash are derived by rolling back the reported net cash flows (+22,429 in FY2019, -16,142 in FY2020, -5,486 in FY2021; Barchart) from the audited FY2021 closing cash of 13,680. ECC loans totalling 8,750 at 31 Dec 2022 were reduced to nil carrying value at 30 June 2023 after 3,000 of repayments and a 9,615 impairment (including accrued interest). Goodwill: nil in all periods. Later data point: cash of A$2.586m was reported in the December 2023 quarter update (TipRanks summary of ASX release). FY2024 balances are not publicly disclosed.

Cash flow

FY2020 and FY2021 operating cash flow figures are as reported by management excluding one-off CannPal acquisition costs (FY2021 commentary). FY2023 operating cash flow includes a A$2.25m stock deposit paid to ECC.

Ratios (computed from audited figures)

ROIC, cash conversion cycle and interest coverage are not meaningful (no debt, negligible sales).

Commentary on trends, inflections and drivers

FY2019–FY2021, the cash-burn phase. AusCann raised significant equity in 2017–2019; FY2019 net cash inflow was A$22.4m. It spent it on cultivation programmes, the Wangara facility and formulation R&D. Annual losses were stable at A$7–9m. Direct R&D ran at about A$2.7–2.9m p.a., about 51% of operating outflows in FY2021. Sales were trivial even after the Neuvis launch: about A$84k in FY2021, per third-party data. The FY2021 loss included a A$2.59m write-down of resin inventory, reflecting collapsing global cannabinoid API prices. That was an early sign that the cost base of a vertically integrated Australian producer was uncompetitive. Net assets nonetheless rose to A$44.4m in FY2021 because the CannPal scrip acquisition added A$17.5m of capitalised IP.

FY2022, the impairment inflection. Within 15 months the CannPal IP was written off in full (A$15.46m). Management attributed the cannabis-sector capital-market collapse to an index drop of more than 85%. The investment property was marked down A$3.85m, and the DayaCann deferred consideration (A$1.42m) was fully provided for. The A$26.4m loss eliminated 59% of book equity. Simultaneously, management redeployed A$5m of the A$13.7m cash pile into a 7.5% secured loan to ECC. That marked the strategic shift from operator to financier and partner.

FY2023, monetisation and a second impairment. Costs were cut hard: employee costs fell 60%, R&D 64% and D&A 90%. The property sale raised A$6.48m net. However, a further A$3.75m was lent to ECC in August 2022 and A$1.0m more in FY2023 (A$4.75m advanced in FY2023 against A$3.0m repaid). The auditor qualified the 1H FY2023 review on recoverability of the A$9.06m ECC exposure. At year end A$9.62m of ECC loans and interest was impaired. Equity fell to A$7.18m, with A$7.01m of it in cash. The going-concern basis relied on the property-sale proceeds.

FY2024 onwards, the opaque period. No further audited accounts were located. Cash had fallen to A$2.59m by the December 2023 quarter. Post-balance-date notes in the FY2023 AFS disclose a further A$1.3m forwarded to ECC on 3 July 2023 and a A$1.25m convertible note issued to ECC (12.5%, 6-month term, secured). The A$1m SPP of January 2024 appears not to have completed: the proposed issue was cancelled on 15 Feb 2024. The company was then removed from the ASX in August 2024. The only post-FY2023 value realisation verifiable in public sources is the April 2026 receipt of 20,000,000 Argent BioPharma (ASX: RGT) shares at a deemed A$0.10 (A$2.0m deemed).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement and Per-Share Data

MetricFY2019FY2020FY2021FY2022FY2023

Product sales (AUD K)

0384250

Cost of goods sold (AUD K)

———-340

Gross profit on sales (AUD K)

———-90

Government grants incl R&D tax incentive (AUD K)

———1,4841,249

Rental income (AUD K)

———427302

Interest revenue (AUD K)

———30619

Total income (AUD K)

———1,9822,170

Direct R&D expense (AUD K)

—2,7072,9481,346490

Employee benefits expense (AUD K)

———1,713680

Depreciation and amortisation (AUD K)

———1,838182

Impairments and fair-value losses (AUD K)

——2,59320,2569,938

Loss before tax continuing (AUD K)

———-24,766-10,701

Net loss after tax (AUD K)

-7,649-7,076-8,641-26,358-10,919

Basic and diluted EPS (AUD cents)

-2.48-2.24-2.45-5.98-2.47

Dividends per share (AUD cents)

00000

Margin Analysis (%)

MetricFY2022FY2023

Gross margin on sales (%)

-38—

Net loss / total income (%)

-1,330-503

Total income growth YoY (%)

—9.5

Balance Sheet

MetricFY2019FY2020FY2021FY2022FY2023

Cash and equivalents (AUD K)

35,31019,16813,6805,7177,010

Total assets (AUD K)

———18,4507,330

Investment property (AUD K)

——11,1117,2000

Loans to ECC (AUD K)

——05,0000

Intangible assets (AUD K)

———00

Total liabilities (AUD K)

———296148

Total borrowings (AUD K)

———00

Lease liabilities (AUD K)

——85400

Net debt (AUD K)

——-13,680-5,717-7,010

Total equity (AUD K)

—34,63644,42818,1547,182

Working capital (AUD K)

———6,7777,169

Accumulated losses (AUD K)

——-49,524-75,139-86,038

Cash Flow

MetricFY2019FY2020FY2021FY2022FY2023

Net operating cash flow (AUD K)

—-10,551-5,759-2,831-3,328

Capex incl building improvements (AUD K)

———-850

Free cash flow (AUD K)

———-2,916-3,328

Net loans advanced to ECC (AUD K)

———-5,000-1,750

Proceeds from property sale (AUD K)

———06,482

Dividends paid (AUD K)

00000

Buybacks (AUD K)

00000

Net change in cash (AUD K)

22,429-16,142-5,486-7,9631,293

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023

ROE on average equity (%)

-84-86

ROA on average assets (%)

—-85

Current ratio (x)

23.949.5

Debt to equity (x)

00

Asset turnover on total income (x)

—0.17

Results by Region

RegionFY2022FY2023

Australia total income (AUD K)

1,9822,170

Chile discontinued income (AUD K)

00

Europe income (AUD K)

00

Share Price and Share Count (million)

MetricFY2019FY2020FY2021FY2022FY2023

Share price at 30 June (AUD)

0.340.1360.100.038—

Shares on issue weighted (million)

———440.5440.5

Implied market cap at 30 June (AUD Mn, derived)

———16.7—

Capital Markets

ItemStatus

Analyst consensus

None (no broker coverage identified)

Dividend history / policy

No dividends ever paid; none expected

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

No borrowings

Capital raising history (selected)

A$5m at A$0.20 (2017 re-listing); CannPal scrip about A$17.5m (2021); A$1m SPP at A$0.016 attempted (Jan 2024, cancelled)

Analyst Conclusions

Management guidance: none issued since the FY2023 accounts. The FY2023 directors' report expected expenditure to "further reduce" in FY2024. Consensus growth expectations: none (no coverage).

Bull case

  1. Option and royalty convexity. If Argent exercises the Neuvis option before about April 2027, AusCann receives a further A$2m in RGT shares plus a perpetual production royalty. That is non-dilutive value on an asset AusCann had written off as uneconomic.

  2. RGT re-rating. AusCann's main asset is now 20m RGT shares. Argent's US$5.5m CannEpil licence with Splash Beverage (Jul 2026), CannPal's Phase 2C success and its US-listing plan could lift that holding materially.

  3. Hidden European value. The retained ECC/EuroCann equity interest, deliberately excluded from the Argent deal, gives exposure to EU-GMP production and German distribution as Germany's medical market expands.

Bear case

  1. Track record of capital destruction. A$93m was raised against A$86m of accumulated losses, and every major capital allocation since 2021 was impaired: CannPal, ECC loans and DayaCann.

  2. Shrinking deal value and illiquidity. The Argent transaction fell from about US$15m to A$2m in five months. Shareholders have no exchange liquidity and no audited accounts since FY2023.

  3. Governance overlap. The same small group of directors spans AusCann, ECC and Argent, and related-party transactions (A$1 CannPal sale, ECC loans) raise questions over whose interests drive outcomes.

Key catalysts and monitorables (next 12 months)

Analyst verdict. AusCann Group Holdings is best understood today not as an operating pharmaceutical company but as a residual holding vehicle at the tail end of a decade-long, largely unsuccessful attempt to build an Australian cannabinoid medicines business. The audited record is unambiguous. Between FY2019 and FY2023 the company generated cumulative product sales of roughly A$112k while recording A$60.6m of net losses. By June 2023 it had shrunk its balance sheet to A$7.2m of net assets, almost all of it cash, with no debt and no staff.

The strategic decisions of 2021–2023 consumed the remaining capital base. The CannPal acquisition was written off within 15 months, A$9.6m of loans to a closely connected European partner were impaired, and the core facility was sold at a loss. The subsequent failure to re-comply with ASX rules and the removal from the Official List in August 2024 stripped shareholders of liquidity and price discovery.

What remains has genuine, if modest, option value. That consists of 20 million Argent BioPharma shares (deemed A$2m), a call on a further A$2m plus royalty if Argent exercises the Neuvis option, an undisclosed equity interest in EuroCann, about A$32m of unrecognised tax losses (derived), and a contested US$1m Chilean receivable. Against that sit an unknown cash position (last reported A$2.59m in December 2023), an unknown liabilities position, and unresolved questions about related-party governance.

For any stakeholder, the decisive near-term monitorable is transparency. Until AusCann lodges current audited accounts, the value attributable to its 440.5 million shares cannot be responsibly estimated. On available evidence we view the equity as a speculative, illiquid residual claim whose outcome depends almost entirely on Argent BioPharma's execution rather than on any AusCann-controlled operating activity. Institutional investors should treat it as uninvestable pending disclosure; existing holders should press the board for audited accounts and a clear capital-return or wind-up plan.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureBackgroundShares (FY2023)

Andrew Chapman

Non-Executive Chair (from 30 Nov 2023); described as Executive Director in 2025–26 counterparty releases

Nov 2023 – (current status at AusCann not confirmed after joining Argent's board in May 2026)

MD of Merchant Group / Merchant Funds Management (historically AusCann's largest shareholder); director of ECC Pharm; Chair of Cycliq Group; former exploration geologist; graduate and postgraduate qualifications in business, finance and hospitality

—

Robert Clifford

Independent NED

Since 1 Apr 2021

Hospitality and food executive (Hyatt, former CEO of Perth Convention Exhibition Centre, EPICURE); Alto Cibum Consulting; former CannPal director

624,380

Brett Mitchell

Independent NED

Since 29 Jun 2023

Corporate finance (Chieftain Securities); co-founded MGC Pharmaceuticals (now Argent BioPharma); Delta Lithium; NED Uvre (UVA); BA Economics

Nil

Tod McGrouther

Independent Chair

14 Dec 2021 – 30 Nov 2023

KTM Capital principal; former BT Australia and Prudential-Bache; director of ECC since 2018; NSX chair; LLB (Hons, University Medal), BFin (Hons)

Nil

Chris Mews

NED to 29 Jun 2023; then CFO (via Merchant Group, A$5k/month)

NED Dec 2019 – Jun 2023

CFO and Company Secretary of Merchant Group; former CFO of PolyNovo; BBus (Acc), CPA

279,689

Susan Park

Company Secretary

FY2022–FY2023

Park Advisory; ex-EY, PwC, Bankwest

—

“—” = not publicly disclosed.

Directors' Remuneration

PersonFees / salarySuperShare-basedTotal

Tod McGrouther (Chair)

88,0000088,000

Chris Mews

122,75000122,750

Robert Clifford

50,0005,250055,250

Krista Bates (to 3 Jan 2023)

26,2420026,242

Brett Mitchell (from 29 Jun 2023)

0000

Layton Mills (CEO, resigned)

272,54221,1017,734301,377

Dr Margaret Curtis

204,84017,1557,058229,053

Total KMP

764,37443,50614,792822,672

Major Shareholders

HolderStakeSource / date

Merchant Funds Management / Merchant Group

Largest shareholder (2019); exact % not publicly disclosed in retrieved sources

ASX release 4 Nov 2019

Layton Mills (DJS Family A/C)

11,387,582 shares (2.58%)

Motley Fool holder data (historical)

Canopy Growth

About 11% at 2016 listing; current holding not disclosed

Ganjapreneur (2016)

Competitive Landscape

Key Competitors

CompetitorListingSegment overlapRelative positioning vs AusCann

Cann Group

ASX: CAN

Australian cultivation and manufacture

Far larger asset base; itself went into voluntary suspension in Nov 2023

Little Green Pharma

ASX: LGP

WA-based GMP cultivator and products

Commercial-scale revenue; a direct WA peer

Argent BioPharma (formerly MGC Pharmaceuticals)

ASX: RGT

Cannabinoid pharma (CannEpil, CimetrA)

Former competitor, now acquirer and partner

Zelira Therapeutics

ASX: ZLD

Clinical cannabinoid medicines

Clinical-stage peer

Bod Science

ASX: BOD

CBD products, pharma pathway

Consumer and pharma hybrid

Emyria

ASX: EMD

Real-world-data-driven cannabinoid / psychedelic medicines

Clinical-data model

Neurotech International

ASX: NTI

Cannabinoid paediatric neurology

Clinical-stage peer

Incannex Healthcare

Nasdaq: IXHL (formerly ASX: IHL)

Cannabinoid combination drugs

Re-domiciled to the US

Vitura Health

ASX: VIT

Distribution and telehealth for medicinal cannabis

Downstream channel leader

Zoetis / Elanco

NYSE

Canine osteoarthritis pain (vs CPAT-01)

Global animal-health majors

Competitor Detail

MetricAusCann FY2023

Product revenue (AUD K)

0

Revenue growth (%)

-100

Net margin (%)

n/m

Direct R&D (AUD K)

490

Recent Developments

It includes counterparty (Argent) disclosures, which are now the main public source on AusCann.

Company Snapshot

2014

Founded

West Perth, Australia

Headquarters

SWOT Analysis

Strengths

  • No debt. Total liabilities were A$148k at 30 Jun 2023, all trade payables and entitlements (FY2023 AFS).
  • Proprietary Neuvis/SEDDS IP with Phase 1 PK data in 25 subjects (FY2021) and improved shelf life and manufacturing time (FY2023). It was valued by Argent at an A$2m option strike plus royalty (Jan 2026).
  • Listed-equity consideration. AusCann now holds 20,000,000 RGT shares (deemed A$2.0m at A$0.10), a liquid asset unlike its prior unlisted stakes (Argent, Apr 2026).
  • Retained European optionality through an equity interest in ECC/EuroCann, expressly excluded from the Argent sale (Argent, 14 Jan 2026).
  • Royalty upside if Argent exercises the Neuvis option: a production royalty on net sales in AusCann's favour (Argent Appendix 1).
  • Large carried-forward tax losses. Unrecognised deferred tax assets on revenue losses were A$8.15m at FY2023, implying about A$32.6m of losses (derived at 25%). Their usability is subject to continuity tests.

Weaknesses

  • No revenue. Product sales were nil in FY2023 and only A$25k in FY2022, with negative gross margin (FY2023 AFS).
  • Value destruction: accumulated losses of A$86.0m against A$93.2m of issued capital (FY2023 AFS).
  • Serial impairments: A$15.46m CannPal IP (FY2022), A$9.62m ECC loans (FY2023), A$5.37m inventory over FY2021–22 and A$1.42m DayaCann.
  • Not listed since 28 Aug 2024, so shareholders have no liquidity or price discovery.
  • No operating team. The CEO left in Sep 2022 and the Head of R&D in Mar 2023; CFO services are outsourced (FY2023 AFS).
  • Disclosure gap. No audited accounts have been located since FY2023, and a 1H FY2023 auditor qualification on ECC recoverability was later validated by the impairment.

Opportunities

  • Argent may exercise the Neuvis option (A$2m in shares plus royalty) before about April 2027.
  • RGT share upside if Argent's CannPal Phase 3 progresses, its CannEpil licensing with Splash Beverage (US$5.5m, Jul 2026) succeeds, or it completes its US dual listing (Argent June 2026 quarterly).
  • German medical-cannabis liberalisation could lift ECC/HAPA value (AusCann Jan 2024 update).
  • The CannEpil CMC in-licence (non-epilepsy) could support a re-launched human programme (Apr 2025 HoA).
  • The corporate shell and tax losses could be used for a recapitalisation or back-door transaction (speculative).
  • Recovery of the disputed DayaCann US$1.0m via Chilean arbitration (FY2023 AFS contingent liability).

Threats

  • RGT price volatility: the deal value fell from about US$15m (Aug 2025) to A$2m (Jan 2026).
  • ECC credit and equity risk: prior loans were impaired and the A$1.25m convertible note outcome is undisclosed.
  • TGA regulatory review (2025) could restrict SAS-B and unapproved products.
  • Price deflation in Australian cannabis products, as evidenced by AusCann's inventory write-downs.
  • Governance and related-party risk from AusCann–ECC–Merchant–Argent director overlaps (filings).
  • Insolvency or deregistration risk if cash is exhausted. The last disclosed cash was A$2.59m (Dec 2023), against FY2023 operating burn of A$3.3m.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
3 Jan 2023NED Krista Bates resignsBoard shrinks to three
28 Feb 20231H FY2023 report: loss A$1.31m; cash A$0.60m; auditor qualified review on A$9.06m ECC exposure; material going-concern uncertaintyRed flag on ECC recoverability
10 Mar 202352% of CannPal sold for A$1 to management-controlled AHHExit of animal-health cost base
31 Mar 2023Head of R&D Dr Margaret Curtis departsLoss of scientific leadership
9 Jun 2023Wangara facility sold for A$6.74mLiquidity restored
29 Jun 2023Brett Mitchell joins board; Chris Mews resigns as NED (becomes CFO)M&A-oriented board
3 Jul 2023Further A$1.3m forwarded to ECCContinued ECC exposure
31 Jul 2023Expanded ECC agreement: exclusive AU/NZ HAPA agencyPotential product revenue
Jul–Oct 2023A$1.25m convertible note issued by ECC to AusCann; new superseding ECC loan agreement after legal review (25 Oct 2023)Restructured credit
25–26 Oct 20233.5m performance rights lapse; FY2023 accounts: loss A$10.92m, A$9.62m impairmentBook equity of A$7.18m
30 Nov 2023Andrew Chapman appointed chair; McGrouther resignsMerchant-aligned leadership
23 Jan 2024Quarterly: cash A$2.586m; ECC loan repayment extended to 31 Mar 2024; European acquisition evaluated; German Cannabis Act change anticipatedRe-compliance strategy
24 Jan 2024SPP up to A$1m at A$0.016Small raise attempt
15 Feb 2024Supplementary prospectus, then proposed issue cancelledRaise / re-compliance stalls
28 Aug 2024Removed from ASX Official List (LR 17.15); CHESS sub-register closed 4 Sep 2024Loss of liquidity for holders
Sep 2024Media report delisting attributed to unpaid listing feesReputational
15 Apr 2025Argent HoA: CannEpil CMC licence for non-epilepsy uses; Neuvis access; deferred fees and royaltiesFirst post-delisting transaction
19 Aug 2025Argent binding term sheet for about US$15m scrip purchase of core assetsHeadline valuation, later cut
27 Aug 2025Argent PR projects a merged company value of about US$100mPromotional; not an AusCann valuation
Nov 2025Argent secures A$11m C/M Capital facility (A$3m immediate drawdown)Funding for the deal
14 Jan 2026Deal restructured to A$2m (20m RGT shares) for 48% CannPal plus Neuvis option; EuroCann excludedRoughly 85–90% lower headline value vs Aug 2025
8 Apr 2026Argent shareholders approve consideration sharesCP satisfied
13 Apr 2026Completion; AusCann receives 20m RGT shares (3-month escrow)Converts illiquid stake into listed paper
6 May 2026Andrew Chapman appointed Executive Director of Argent; Roby Zomer becomes Non-Executive ChairmanLeadership overlap AC8–RGT
Jun 2026 quarterCannPal (now Argent's 48% associate) completes Phase 2C dose confirmation for CPAT-01 and plans Phase 3Upside now accrues to Argent
Jul 2026Chapman transitions to Non-Executive Director at ArgentGovernance change
~13 Jul 2026Escrow on AusCann's RGT shares expires (3 months from issue; derived)AusCann free to sell RGT shares

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Income Statement: Revenue & Gross Profit: Product sales held from AUD 0 Mn in FY2019 to AUD 0 Mn in FY2023.
AusCann Group Holdings Ltd — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2019FY2020FY2021FY2022FY2023
Product sales000.100
Cost of goods sold———-00
Gross profit on sales———-00
Interest revenue———00.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. AusCann Annual Financial Statements, year ended 30 Jun 2023 (signed 26 Oct 2023), — Primary (audited) — Sections 1, 4–6, 9, 11, 13, 17–19 (clients3.weblink.com.au)
  2. AusCann Appendix 4D, half-year to 31 Dec 2022 (28 Feb 2023), ASX — Primary (reviewed) — ECC loans, suspension, auditor qualification, Wangara lease
  3. AusCann Appendix 4D, half-year to 31 Dec 2021 (28 Feb 2022), ASX — Primary — 1H FY22 results
  4. AusCann FY2021 results commentary (30 Aug 2021), via Strawman — Primary (reproduced) — FY2020–21 figures
  5. ASX release 18 Mar 2021 (CannPal scheme implementation) — Primary — M&A
  6. ASX releases 4 Nov 2019, 7 May 2020, 4 Dec 2020 — Primary — Board and CEO changes
  7. AusCann ASX release 23 Jan 2024 (quarterly) — Primary — 2024 status
  8. ASX Notice 0092.17.02 (1 Feb 2017) and ASX Notice 1019.24.09 (6 Sep 2024) — Primary (exchange) — Listing and removal
  9. Argent BioPharma ASX releases 19 Aug 2025, 14 Jan 2026, 13 Apr 2026, 6 May 2026; Dec 2025 and Jun 2026 quarterlies — Primary (counterparty) — 2025–26 transactions
  10. Market Index (AC8), InvestSmart, Motley Fool, MarketScreener, MT Newswires (moomoo), Barchart, roic.ai — Aggregators — Former names, announcement log, holdings, chair appointment, legacy sales data
  11. Business News Australia (10 Mar 2023); Biotech Dispatch, Stockhead, SmallCaps, Cannabiz (2025) — Media — Deal context
  12. Wikipedia (AusCann) — Secondary — Founding and history (scaling errors noted)
  13. Prohibition Partners, GrowerIQ, IMARC, Towards Healthcare, MJBizDaily / FreshLeaf — Industry research — Market sizing

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.